Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III infant primary and booster vaccination study of Hib-MenC plus Infanrix-IPV versus licensed MenC vaccine plus Pediacel
2004-003769-33Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of Hib-MenC-TT, tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine, diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine and Meningococcal group C polysaccharide conjugate vaccine in Haemophilus influenzae type b disease (Hib) and meningococcal group C disease (2 arms), sponsored by GSK. Primary endpoints: Primary vaccination immunogenicity and Booster phase immunogenicity. Started Jul 2005; status: completed.
02
Drugs
Hib-MenC-TTtetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccinediphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccineMeningococcal group C polysaccharide conjugate vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)meningococcal group C disease
Beyond the preview
Go deeper on 2004-003769-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003769-33.